Cellect Biotechnology Ltd. announced that it has entered into and commenced a collaborative development program with XNK Therapeutics. Under the terms of the agreement, Cellect will help improve XNK Therapeutics’ technology platform, for targeting cancer across a wide range of indications. Cellect expects to expand the business arrangement based on the outcomes of the ongoing studies at XNK Therapeutics. Cellect’s functional cell selection technology has the potential to significantly improve the consistency and manufacturing efficiency in autologous as well as future allogeneic transplantation. XNK Therapeutics is expected to leverage Cellect’s simple, safe and inexpensive process as part of its efforts to create the next generation version of its innovative therapy platform.